A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, vol.42, no.1, pp.40-47, 2018 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 42 Issue: 1
- Publication Date: 2018
- Doi Number: 10.1016/j.clinre.2017.06.008
- Journal Name: CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.40-47
- Istanbul University Affiliated: Yes
Abstract
Background: Entecavir (ETV) and tenofovir disoproxil fumarat (TDF) are the two first-line therapies recommended in the treatment of chronic hepatitis B because of having potent antiviral effect and high genetic barriers against resistance. We aimed to compare efficacy of these drugs and to evaluate predictors of viral suppression.